CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,011 enrolled
Drug / intervention
Desloratadinedrug
Likely dose
Desloratadine 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724698
NCT00724698N/ACompleted
CompareCT.gov

Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients

Organon and Co·observational·Posted Jul 29, 2008·Updated Feb 9, 2022

In Brief

An observational study evaluating Desloratadine for Rhinitis and Urticaria. Completed, enrolled 3,011 participants.

Detailed Summary

Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Urticaria
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 29, 2008
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.9 years ago

Interventions

Desloratadinedrug

Desloratadine 5 mg once daily